RSV vaccines are moderately to highly effective at preventing serious RSV illness, especially hospitalizations and severe lung infections, but protection is not 100% and tends to be strongest in the first season after vaccination. They work best at reducing severe outcomes (like hospitalization and severe lower respiratory tract disease) rather than stopping every mild infection or cold-like symptom.

How effective are RSV vaccines?

  • In adults 60+, one major vaccine (Arexvy) has shown around 77% effectiveness at preventing RSV-related emergency department visits and about 83% effectiveness at preventing RSV-related hospitalizations in real‑world data.
  • A large review of clinical trials reported about 77% protection against RSV-related lower respiratory tract disease (like pneumonia and bronchitis) and about 67% protection against RSV-related acute respiratory illness in older adults.
  • For severe disease in older adults, another RSV vaccine (RSVpreF/RSVpreF3) has shown very high efficacy against severe RSV-associated lower respiratory tract disease, above 90% in some phase 3 trial analyses, meaning a strong reduction in the worst outcomes.

Protection in infants via maternal vaccination

  • When RSV vaccine is given during pregnancy, studies show it can reduce an infant’s risk of needing medical care for RSV-related lower respiratory tract disease by about 54% and cut severe RSV disease by about 74% in early life.
  • These maternal vaccines also lowered the risk of RSV-related hospitalization in babies by about 54%, which is important because RSV is a leading cause of hospitalization in young infants.

How long does protection last?

  • Protection appears strongest in the first RSV season after vaccination and then gradually wanes. In one large trial of an older-adult vaccine, efficacy against RSV-related lower respiratory tract disease started above 80% in the first season and fell to around the mid‑50% range by the second and under 50% by the third.
  • Real‑world work following older adults over two seasons found that a single RSV shot reduced hospitalization risk by about 69% in the first year and about 48% in the second, still offering meaningful but lower protection over time.

Safety and “big picture” effectiveness

  • Systematic reviews and meta‑analyses up to 2024–2025 conclude that licensed RSV vaccines are generally safe and effective for both older adults and pregnant people, without major new safety signals emerging in trials.
  • Health agencies note that, like all vaccines, RSV shots can have side effects (typically mild, such as soreness, fatigue, or low‑grade fever) and there is a very small risk of serious reactions, so recommendations are targeted to higher‑risk groups like adults 60+ and pregnant people during specific weeks of gestation.

When does getting it “make sense”?

  • Adults 60+ and especially those with chronic heart or lung disease, weakened immune systems, or living in long‑term care stand to gain the most, because they face a higher chance of hospitalization from RSV.
  • Pregnant people offered the vaccine (following local guidance) can significantly lower the chance that their newborn will have severe RSV or need hospital care in the first months of life, making maternal vaccination a key strategy alongside infant monoclonal antibodies where available.

Bottom line: RSV vaccines are not perfect shields against infection, but they are quite effective at keeping high‑risk adults and young infants out of the hospital and reducing the severity of disease.

Information gathered from public forums or data available on the internet and portrayed here.